Interventions
EVENT
Patients randomised to the SpiroDex group received oral spironolactone 50 mg once daily (as two tablets of 25 mg) on day 1, followed by 25 mg once daily until day 21. All patients received standard of care which included supportive measures for SARS-CoV-2 and approved therapies at the time as per Government of India guidelines (which included remdesivir for 26.1% of standard of care patients and 23.0% of patients within the SpiroDex group). Dexamethasone was given from day one at a dose of 3 mg twice daily for ten days. The control arm received two placebo tablets on day one, followed by one placebo tablet daily until day 21.In the event of hospital discharge, dexamethasone was continued until day 10 in both groups, as per treatment guidelines. Spironolactone 25 mg was continued for a total period of 21 days in the trial group. Placebo tablets were continued until day 21 in the control arm. All patients were followed up with a telephone call at day 28 from the day of enrolment.If a National Early Warning Score (NEWS2) score [